RPN-001 (leflutrozole)
Male Infertility (Hypogonadism)
Phase 2Active
Key Facts
About ReproNovo
ReproNovo is a private, clinical-stage biotech company targeting significant unmet needs in reproductive health, including male infertility and adenomyosis. The company's most advanced program, RPN-001 (leflutrozole), is in Phase 2 clinical trials in the U.S. and has received clinical trial approval in China. Backed by a seasoned leadership team and specialized international investors, ReproNovo is positioned to advance novel therapies in a large and growing global market.
View full company profile